Hims & Hers Health Inc. Stock News

NEWTOWN, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Hims & Hers Health, Inc. (“Hims”) (NYSE: HIMS), resulting from allegations of providing potentially misleading business information to the investing public.

NEW YORK , July 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership and regulatory scrutiny on GLP-1 drugs pose significant long-term growth risks. Despite Amazon's entry into telehealth, Hims maintains a strong niche with high subscriber growth and improved gross ...

LOS ANGELES, July 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).

The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets, including $6.5B in 2030 revenue, are driven by personalized services, global expansion, and not dependent on branded drug deals. The ZAVA acquisition and European expansion offset any short-term disruption, ...

Novo Nordisk just killed the deal. But Hims might come out even stronger. Here's why the market got it wrong. GLP-1s are just the tip of the iceberg. Hims is quietly positioning itself as the gateway to the next wave of medical breakthroughs. The stock plunged more than 40%, but our DCF shows it could be worth $70-plus. This might be the best buying opportunity yet.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A L...

Hims & Hers (HIMS 6.81%) stock investors desperately need some positive news following the stock price crash in late June.